On Wednesday, Shares of Wells Fargo & Co (NYSE:WFC), lost - 0.83% to $57.06.
Wells Fargo Insurance, part of Wells Fargo & Company (WFC), declared that two of its sales executives, Russell Bank and Billy Bray, won Business Insurance magazine’s 40 Under 40 Broker Awards. In its third year, the 40 Under 40 program recognizes leadership attributes, client service skills and expertise among retail insurance brokers under age 40.
“We are thrilled that our team members have been recognized as top performers and industry leaders,” said Laura Schupbach, head of Wells Fargo Insurance. “Russell and Billy are outstanding representatives of Wells Fargo’s commitment to provide our customers with best-in-class service and innovative solutions that assist them succeed financially.”
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of Mylan NV (NASDAQ:MYL), declined -1.18% to $55.09, during its last trading session.
Mylan N.V., confirmed that the company has been sued by BTG International Ltd., Janssen Biotech, Inc., Janssen Oncology, Inc., and Janssen Research & Development, LLC in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Abiraterone Acetate Tablets, 250 mg. This product is the generic version of Zytiga, which is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and anticipates to be eligible for 180 days of marketing exclusivity upon final FDA approval. The plaintiffs have filed a lawsuit against Mylan in the United States District Court for the District of New Jersey.
For the 12 months ending June 30, 2015, Zytiga had U.S. sales of about $1.08 billion, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, Bank of Montreal (USA) (NYSE:BMO), ended its last trade with - 1.21% loss, and closed at $54.58.
BMO Asset Management Inc., declared the August 2015 cash distributions for certain BMO Exchange Traded Funds (ETFs) that distribute monthly. Unitholders of record of the BMO ETFs at the close of business on August 28, 2015 will receive cash distributions payable on September 4, 2015.
Commissions, administration fees and expenses all may be associated with investments in exchange traded funds. Please read the prospectus before investing. Exchange traded funds are not guaranteed, their values change frequently and past performance may not be repeated.
Bank of Montreal offers various banking products and services in Canada, the United States, and internationally. The company’s personal and commercial banking products and services comprise chequing and savings accounts; banking services, counting 24/7 banking, direct deposits, bill payments, overdraft services, money transfers, wire transfers, and travel insurance; credit cards; mortgages; loans and lines of credit; and creditor insurance.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
